Radiomicrosphere Therapy (RMT) refers to a liver-directed therapeutic modality based on the intrahepatic arterial administration of radiolabeled microspheres. There is a need for standardization of the terminology of RMT. A descriptive identifier should first name the radioisotope, then the chemical formulation of the microsphere, and lastly add the term RMT that indicates the therapeutic modality. At present, clinically available options include /Y-90/ /Resin/ /RMT/, /Y-90/ /Glass/ /RMT/ and /Ho-166/ /PLLA/ /RMT/. The latter is available in Europe and is being considered for clearance by the FDA in the United States. Preclinical studies with /Re-188/ /PLLA/ /RMT/ are underway. Dosimetric considerations are strongly tied to both the type of the radioisotope and the chemical composition of the microsphere type. This review will focus on Y-90 resin and glass RMT, the history, dosimetry, clinical use, and controversies. (C) 2022 Elsevier Inc. All rights reserved.
机构:
Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USAHarvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
Dzik, S
INFUSIONSTHERAPIE UND TRANSFUSIONSMEDIZIN,
1998,
25
(05):
: 282
-
287
机构:
Edith Cowan Univ, Ctr Precis Hlth, Perth, WA 6027, Australia
Capital Med Univ, Sch Publ Hlth, Municipal Key Lab Clin Epidemiol, Beijing 100069, Peoples R China
Shandong First Med Univ & Shandong Acad Med Sci, Sch Pharmaceut Sci, Tai An 271016, Peoples R China
Shantou Univ, Affiliated Hosp 1, Med Coll, Shantou 515041, Peoples R ChinaEdith Cowan Univ, Ctr Precis Hlth, Perth, WA 6027, Australia